The KEAPSAKE trial examines the efficacy of the same glutaminase inhibitor – telaglenastat – combined with the standard-of-care pembrolizumab and chemotherapy in NSCLC patients mutated in KEAP1 using STK11/LKB1 status for the stratification (https://clinicaltrials.gov). Here, KEAP1 is linked to non-small cell lung carcinoma.